Last updated on September 2017

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.


Brief description of study

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

Detailed Study Description

The objective of this randomized phase III open label trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival compared to enzalutamide single agent in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

For Study Locations, Click Here

Clinical Study Identifier: TX153168

Contact Investigators or Research Sites near you

Start Over

Research Center

Research Center
Additional Locations, XX Belgium
  Connect »

Research Center

Research Center
Additional Locations, XX Italy
  Connect »

Research Center

Research Center
Additional Locations, XX Poland
  Connect »

Research Center

Research Center
Additional Locations, XX Spain
  Connect »

Research Center

Research Center
Additional Locations, XX United Kingdom
  Connect »

Research Center

Research Center
Additional Locations, XX Denmark
  Connect »

Research Center

Research Center
Additional Locations, XX Switzerland
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.